Pfizer signs companion diagnostic deal for cancer vaccine candidate
This article was originally published in Scrip
Pfizer and DxS, a subsidiary of Qiagen, are to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in Phase II testing for the treatment of the brain cancer glioblastoma multiforme.
The companion diagnostic will be developed and manufactured at Qiagen's centre of excellence for companion diagnostics in Manchester, UK. It will be a real-time PCR assay used to detect EGFRvIII RNA in tumour tissue.
The companies did not disclose further financial details for the deal.
Pfizer licensed the vaccine candidate from Celldex in 2008.